A preface to the special issue “Pediatric tumors” DOI Open Access
Giampietro Viola

Biochemical Pharmacology, Journal Year: 2023, Volume and Issue: 217, P. 115844 - 115844

Published: Oct. 4, 2023

Language: Английский

The Intersections between Neuroscience and Medulloblastoma DOI
Yafei Wang, Ying Yu, Jiahua Yu

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217660 - 217660

Published: March 1, 2025

Language: Английский

Citations

0
Multifocal medulloblastoma in an adult: a case report and review of the literature DOI
Chengwen Luo, Fei Zhang, Xiaofeng Zhu

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: April 15, 2025

Abstract Background: Medulloblastoma (MB) is a highly aggressive tumor originating in the cerebellum, predominantly affecting children. Adult medulloblastoma rare, leading to lack of standardized treatment protocol. Although multimodal strategies from pediatric MB have improved outcomes adult patients, challenges persist, including early diagnosis difficulties, toxicity, recurrence risks, targeted therapies, and controversies over chemotherapy timing regimen. Case Description: We present clinical case involving 53-year-old male patient diagnosed with multifocal medulloblastoma, who presented symptoms dizziness. Cranial magnetic resonance imaging (MRI) revealed space-occupying lesions right cerebellar infratentorial region temporal pole, which were initially suspected be meningiomas. The subsequently underwent surgical resection subtentorial lesion, was pathologically confirmed medulloblastoma. Molecular classification through genetic testing classified it as SHH subtype. Postoperatively, received sequential radiotherapy chemotherapy. After radiotherapy, lesion pole disappeared, recovered well. Disease-free survival this more than 2 years, during returned hospital for follow-up every three months. Currently, good condition no significant sequelae or signs recurrence. Conclusion: even rarer. we report surgery followed by chemotherapy, resulting favorable prognosis. This may suggest that postoperative combined could effective controlling

Language: Английский

Citations

0
Multifocal medulloblastoma in an adult: a case report and review of the literature DOI Creative Commons
Chengwen Luo, Fei Zhang, Xiaofeng Zhu

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2025, Volume and Issue: 151(5)

Published: May 15, 2025

Language: Английский

Citations

0
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis DOI
Derek Dang, Akash Deogharkar,

John McKolay

et al.

Cancer Cell, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Citations

0
Clinical advances in analytical profiling of signature lipids: implications for severe non-communicable and neurodegenerative diseases DOI
Sutanu Sarkar, Deotima Roy, Bhaskar Chatterjee

et al.

Metabolomics, Journal Year: 2024, Volume and Issue: 20(2)

Published: March 8, 2024

Language: Английский

Citations

1
Overcoming Treatment Resistance in Medulloblastoma: Underlying Mechanisms and Potential Strategies DOI Open Access
Hasan Slika,

Aanya Shahani,

Riddhpreet Kaur Wahi

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(12), P. 2249 - 2249

Published: June 18, 2024

Medulloblastoma is the most frequently encountered malignant brain tumor in pediatric population. The standard of care currently consists surgical resection, craniospinal irradiation, and multi-agent chemotherapy. However, despite this combination multiple aggressive modalities, recurrence disease remains a substantial concern, treatment resistance rising issue. development results from interplay myriad anatomical properties, cellular processes, molecular pathways, genetic epigenetic alterations. In fact, several efforts have been directed towards domain characterizing major contributors to resistance. Herein, review highlights different mechanisms that drive relapse are implicated occurrence discusses them context latest molecular-based classification medulloblastoma. These include impermeability blood-brain barrier drugs, overactivation specific resistant multipotent nature cancer stem cells, intratumoral intertumoral heterogeneity, metabolic plasticity. Subsequently, we build on explore potential strategies targeted agents can abrogate these mechanisms, undermine resistance, augment medulloblastoma’s response therapeutic modalities.

Language: Английский

Citations

1
A preface to the special issue “Pediatric tumors” DOI Open Access
Giampietro Viola

Biochemical Pharmacology, Journal Year: 2023, Volume and Issue: 217, P. 115844 - 115844

Published: Oct. 4, 2023

Language: Английский

Citations

0